RE:Here is our closest competitor according to our presentation
To be fair, the primary endpoint of this study should have data after 12 months. If the results are good, secondary endpoints probably won't be needed to continue with FDA approval. In the presentation Berendt mentioned that if MCNA is approved, any competition will need to have a comparator arm study against MCNA to gain approval. So while the Vicinium compound looks promising, it doesn't seem like it will be a real near term threat to TST if MCNA gains approval. If MCNA doesn't gain approval, then Telesta has more pressing issues to deal with than worrying about competition.